SEC – ‘UPLOAD’ from 4/15/22 re: Alterola Biotech Inc. – ‘TEXT-EXTRACT’

On:  Friday, 4/15/22, at 2:30pm ET   ·   Delayed-Release:  Filing ¶  –  Release Delayed   ·   Accession #:  0-22-4095

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Comment or Other Letter from the SEC   —   Delayed-Release

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: LETTER      Comment or Other Letter from the SEC                 PDF     27K 
 2: TEXT-EXTRACT  Comment or Other Letter from the SEC - PDF's         1      5K 
                Text                                                             

‘TEXT-EXTRACT’   —   Comment or Other Letter from the SEC – PDF’s Text

United States securities and exchange commission logo                           

April 15, 2022              

Timothy Rogers                                                    
Chairman                                                          
Alterola Biotech, Inc.                                            
47 Hamilton Square Birkenhead Merseyside                          
CH41 5AR United Kingdom                                           

                                                     Re: Alterola Biotech,
Inc.                                                                            
                                                    Registration
Statement on Form S-1                                                           
                                                           Filed April 7, 2022
                                                           File No. 333-264178

Dear Mr. Rogers:                                                  

        This is to advise you that we have not reviewed and will not
review your registration                                                        
statement.                                                        

      Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you                                                     
      that the company and its management are responsible for the accuracy and
adequacy of their                                                               
     disclosures, notwithstanding any review, comments, action or absence of
action by the staff.                                                            

                                                    Please contact Chris
Edwards at 202-551-6761 with any questions.                                     

Sincerely,                  

   Division of Corporation Finance

Office of Life Sciences     
cc:                                              Scott Doney, Esq.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘UPLOAD’ Filing		Date		Other Filings
Filed on:		4/15/22		UPLOAD
		4/7/22		S-1,  UPLOAD
				List all Filings